India's diabetes and weight-loss drug market is set for a major shift. Novo Nordisk's popular drug semaglutide is now off patent. Over 40 companies are launching more than 50 affordable generic versions. This move aims to make these treatments accessible to millions more Indians. The market is expected to grow significantly in the coming months.